SAM #CDC-75D301-Presolicitation-MfgDMNPatch

This opportunity from the CDC seeks a manufacturer for a dissolving microneedle patch to deliver rotavirus vaccine in a clinical trial. - Sole source procurement to Micron Biomedical Incorporated - Purpose: Manufacture dissolving microneedle (MN) patch for live attenuated rotavirus vaccine delivery - Intended for use in CDC clinical trial under NCIRD - No specific part numbers or quantities provided - Justified under FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1) as only one responsible source - NAICS code: 541715 (R&D in Physical, Engineering, and Life Sciences) - Requirements: - Demonstrated capability to manufacture MN patch for vaccine delivery - Ability to provide warranties and proof of manufacturing capability - Interested parties must submit detailed capability statements (management, technical, cost) - Period of performance: April 15, 2026 – April 14, 2028 - Place of performance and contracting office: CDC Office of Acquisition Services, Atlanta, GA

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Centers for Disease Control and Prevention (CDC) National Center for Immunizations and Respiratory Diseases (NCIRD) intends to award a Firm Fixed Price Contract to Micron Biomedical Incorporated 311 FERST Drive NW STE L1309 Atlanta, Georgia 30318-5602. Under the authority of FAR 13.106-1(b)(1)(i) and 10U.S.C. 2304(c)(1), only one responsible source and no other supplies or services will satisfy agency requirements. The requirement is to manufacture microneedle (MN) patch to deliver live attenuated rotavirus vaccine for use in a planned clinical trial in the future.

The Period of Performance is from 4/15/2026 thru 04/14/2028.

The anticipated award date of this action is on or before April 24, 2026. The applicable NAICS code is 541715: Research and Development In The Physical, Engineering And Life Sciences (Except Nanotechnology And Biotechnology). This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the warranties and proof as being capable of providing the requesting services. Capability Statements shall not exceed 2 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability Statements are due by 10:00 AM Eastern Standard Time (EST), April 8, 2026. Capability Statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to Tim Williams email address at: TPW8@cdc.gov NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.